Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Event-free survival	3-year
Secondary	Liposomal cytarabine toxicity	3 years
Secondary	CNS relapse rate	3-year
Secondary	Overall survival	3-year
Secondary	Leukemia-free survival	3-year
Secondary	Efficacy of hydrocortisone premedication for reduced PEG-asparaginase allergic reactions	3 years
Secondary	PEG-asparaginase toxicities	3 years
Secondary	Complete and overall response rates	3 years
Secondary	Non-relapse mortality	3-year
Other	Minimal residual disease and outcomes	3 years
Other	Asparaginase antibodies and asparaginase activity	3 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02043587/registered